Takeda’s Hyqvia Shows Promise for CIDP in Phase 3 Study

Takeda’s investigational drug Hyqvia (immune globulin with recombinant human hyaluronidase) showed promise in a late-stage clinical trial for patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

In the phase 3 study, Hyqvia significantly reduced relapse of neuromuscular disability and impairment when used as a maintenance therapy compared with placebo.

Takeda said the subcutaneous immunoglobulin solution could allow for monthly infusions in many CIDP patients.

Hyqvia is already FDA-approved to treat adult patients with primary immunodeficiency. The company plans on submitting an application to the FDA for the new indication this year.